The latest price target for AIM ImmunoTech (AMEX:AIM) was reported by Ascendiant Capital on December 10, 2024. The analyst firm set a price target for $4.50 expecting AIM to rise to within 12 months (a possible 2268.42% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for AIM ImmunoTech (AMEX:AIM) was provided by Ascendiant Capital, and AIM ImmunoTech maintained their buy rating.

There is no last upgrade for AIM ImmunoTech

There is no last downgrade for AIM ImmunoTech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AIM ImmunoTech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AIM ImmunoTech was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

While ratings are subjective and will change, the latest AIM ImmunoTech (AIM) rating was a maintained with a price target of $5.00 to $4.50. The current price AIM ImmunoTech (AIM) is trading at is $0.19, which is out of the analyst’s predicted range.